Page 180 Guide to Pain Management in Low-Resource Settings

168 Th omas Jehser

rather by titration in small repetitive doses until complimentary, alternative, or traditional medi-
an eff ective dose is achieved. cine are not justifi ed.
• Th e positive eff ects of morphine far outweigh the
risk of respiratory depression by opioids, since ti- References
tration allows fi nding the balance between reduc-
tion of dyspnea and the typical side eff ect of re- [1] Alberg AJ, Samet JM Epidemiology of lung cancer. Chest 2003;123:21.
[2] American Th oracic Society. Dyspnea: mechanisms, assessment and
spiratory depression. management, a consensus statement. Am J Respir Crit Care Med
• Morphine should be given subcutaneously to al- 1999;159:321.
[3] Bruera E, MacEachern T, Ripamonti C, Hanson J. Subcutaneous mor-
low fast onset of action in acute situations of dys- phine for dyspnea in cancer patients. Ann Intern Med 1993;119:906.
[4] Colice GL. Detecting lung cancer as a cause of hemoptysis in pa-
pnea, if the intravenous route is not available. tients with a normal chest radiograph: bronchoscopy vs. CT. Chest
• Patients with dyspnea in end-stage lung cancer 1997;111:877.
[5] Harrington SE, Smith TJ. Th e role of chemotherapy at the end of life:
not only need pharmacotherapy, but especially “when is enough, enough?” JAMA 2008;299:2667.
require a team of caring family members, health [6] Holty JEC, Gould MK. When in doubt should we cut it out? Th e role of
surgery in non-small cell lung cancer. Th orax 2006;61:554.
care workers, friends, and spiritual advisors. [7] Silvestri GA, Spiro SG. Carcinoma of the bronchus 60 years later. Th o-
rax 2006;61:1023.
• Anything that helps the patient should be used, [8] Toloza EM, Harpole L, McCrory DC. Noninvasive stating of non-small
because in palliative care, reservations about cell lung cancer: a review of current evidence. Chest 2003;123:137.